Skip to Content
Top

Immunotherapy, which stimulates the patient’s own immune system to attack cancer, has shown promise in treating a variety of cancer types with long-term responses. This class of therapy involves a range of treatments, including checkpoint blockade inhibitors, vaccines and cell-based therapies.

MD Anderson’s adoptive-cell therapy (ACT) platform, which supports the Moon Shots Program™ was established to develop promising new...

BY Lany Kimmons

For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special Awards...

BY Laura Sussman

Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared...

BY Laura Sussman

In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held promise for replacing standard chemotherapy treatment, shrank tumors in only 15 to 20 percent of patients.

An international Phase II trial led by MD Anderson researchers may provide an alternative. The trial showed that treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated...

BY Laura Sussman

In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...

BY Clayton R. Boldt, Ph.D.

Understanding evolution within cancer cells is a longtime interest for Nicholas Navin, Ph.D., an associate professor of Genetics and Bioinformatics...

BY Laura Sussman

In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved...

BY Sarah Watson

Eight MD Anderson researchers have been selected as the newest class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship...

BY Michael Hardy

Shortly after arriving at MD Anderson in 1987 as a junior faculty member, Guillermina Lozano, Ph.D., attended several seminars hosted by the...

BY Payal Pandit Talati, MPH

Reducing the incidence of melanoma through primary and secondary prevention is among one of the shared goals and key partnership strategies...

BY Clayton R. Boldt, Ph.D.

Each May, Skin Cancer Awareness Month serves as a reminder of how individuals can work to lower their risk of skin cancer – the most common...

BY Bryan Tutt

Patients with recurrent or second primary head and neck cancer who previously received radiation therapy to the head and neck region – especially...

BY Ron Gilmore

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that doesn’t rely on the hormones estrogen and progesterone or the...

BY Clayton Boldt, Ph.D.

By July 31, all U.S. Department of Housing and Urban Development (HUD) housing will be required to be smokefree, in accordance to rule put...

BY Scott Merville

Immunotherapy has taken hold as an effective treatment for a variety of advanced cancers, but so far, colorectal cancer has...

BY Scott Merville

Immune cells that rush to repair damage caused by inflammatory tissue are subverted to cancer-promoting allies by pancreas cells that feature...

BY Clayton R. Boldt, Ph.D.

Fewer than 30% of the women in the U.S. with abnormal, benign lesions known as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS...

BY Clayton R. Boldt, Ph.D.

Despite the availability of vaccines that could prevent the majority of cancers caused by the human papillomavirus (HPV), the incidence of...

BY MD Anderson staff

“Driving Innovative Cancer Science to Patient Care” was the theme of the American Association for Cancer Research’s annual meeting, which...

BY Ron Gilmore

The American Association for Cancer Research (AACR) has selected Isaiah J. Fidler, D.V.M., Ph.D., professor of Cancer Biology, as recipient...

BY Scott Merville

Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...

BY Ronda Wendler

When people breathe, there’s movement inside their bodies.

Organs, tissues and even cancer patients’ tumors move around all the time...

BY Ron Gilmore

MD Anderson was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30% of the $73.5...

BY Clayton Boldt, Ph.D.

MD Anderson’s Colorectal Cancer Moon Shot™ is committed to the prevention and early detection of the third most common cancer diagnosed in...

BY Ron Gilmore

Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...

BY Bryan Tutt

Radiation therapy to the whole breast or chest wall and the internal mammary lymph nodes can deliver a radiation dose to the heart that increases...

BY Scott Merville

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...

BY Scott Merville

A cold virus engineered to attack the most common and deadly of brain tumors allowed 20% of patients with recurrent glioblastoma to live for...

BY Scott Merville

Organizations in Spain and Saudi Arabia recognized the leadership of Jim Allison, Ph.D., MD Anderson chair of Immunology, in cultivating the...

BY Scott Merville

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...

BY Ron Gilmore

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could...

BY Lany Kimmons

In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from MD Anderson Cancer...

BY Clayton Boldt, Ph.D.

Increasing the dosage of a prescription smoking cessation medication by 1 milligram a day – from 2 to 3 milligrams – more than doubled abstinence...

BY Joe Munch

Chemotherapy is a proven and effective method for treating many types of cancer, but up to 90% of patients who receive the treatment develop...

BY Clayton Boldt, Ph.D.

Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid...

BY Sarah Bronson

Until recently, patients with esophageal cancer were treated with esophagectomy, or removal of the affected part of the esophagus and surrounding...

BY Ron Gilmore

A new genetic-based model developed by an MD Anderson research team may explain how a common form of early-stage breast cancer known as ductal...